BioTel Heart has expanded its 24/7 remote arrhythmia monitoring services using MCOT (Mobile Cardiac Outpatient Telemetry) to include serial QTc measurements in COVID-19 patients to support the safe delivery of medications that may prolong the QT interval and lead to ventricular arrhythmias. As part of its FDA 510(k) clearance, MCOT has a specific indication for use with patients requiring measurement, analysis, and reporting of the QT interval.
Minimum twice daily QTc measurement
24/7 monitoring and near real-time notifications1
Up to 30 days of continuous monitoring
Disposable Patch or lead wire option
1 Per provider predetermined protocol
Reduces Burden on Healthcare System
As the inpatient volume of COVID-19 patients continues to rise, the ability to monitor every patient that is receiving drugs that can prolong the QT interval in the telemetry unit is not possible. With MCOT patient monitoring, we have access to near real-time information needed to facilitate a clinical intervention prior to an arrhythmia occurring and a solution that significantly reduces the number of potential exposures to healthcare workers and reduces the need for critical PPE.
Laurence Epstein, MD
System Director Electrophysiology
To protect patients from the dangers of QTc interval prolongation in any setting, patients can be enrolled in the COVID-19 monitoring program without setting foot into an office or clinic with our well-establish mail-to-home process.